CU22545A1
(es)
*
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
AU662311B2
(en)
*
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
CN1063489C
(zh)
*
|
1993-06-29 |
2001-03-21 |
生化学工业株式会社 |
新多肽及编码该多肽的dna
|
UA40577C2
(uk)
*
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
DE69428764T2
(de)
*
|
1993-12-24 |
2002-06-20 |
Merck Patent Gmbh |
Immunokonjugate
|
GB9401182D0
(en)
*
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
US6448077B1
(en)
*
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
US20030108545A1
(en)
*
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
US6017719A
(en)
*
|
1994-06-14 |
2000-01-25 |
Nexell Therapeutics, Inc. |
Positive and positive/negative cell selection mediated by peptide release
|
ATE208633T1
(de)
*
|
1994-09-16 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
US7803904B2
(en)
*
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US6551593B1
(en)
*
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
IT1277827B1
(it)
*
|
1995-03-01 |
1997-11-12 |
Ministero Uni Ricerca Scient E |
Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
|
EP0739984A1
(en)
*
|
1995-04-26 |
1996-10-30 |
San Tumorforschungs-Gmbh |
Bivalent polypeptides containing at least two domains
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1978033A3
(en)
*
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
US5641751A
(en)
*
|
1995-05-01 |
1997-06-24 |
Centocor, Inc. |
Tumor necrosis factor inhibitors
|
DE69616651D1
(de)
*
|
1995-05-26 |
2001-12-13 |
Merck Patent Gmbh |
Antiidiotypische Antikörper die eine Immunantwort gegen den Rezeptor für epidermalen Wachstumsfaktor induzieren
|
EP0745612B1
(en)
*
|
1995-05-26 |
2001-11-07 |
MERCK PATENT GmbH |
Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
EP0781847A1
(en)
|
1995-11-06 |
1997-07-02 |
MERCK PATENT GmbH |
Humanized monoclonal antibody
|
AR005035A1
(es)
*
|
1995-12-11 |
1999-04-07 |
Merck Patent Ges Mit Beschränkter Haftung |
Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
|
DE69724428T3
(de)
|
1996-06-07 |
2009-07-23 |
Poniard Pharmaceuticals, Inc., Seattle |
Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
AU4208897A
(en)
*
|
1996-09-16 |
1998-04-02 |
Merck Patent Gmbh |
Oligocistronic expression system for the production of heteromeric proteins
|
CA2616914C
(en)
*
|
1996-12-03 |
2012-05-29 |
Abgenix, Inc. |
Egfr-binding antibody
|
EP1325932B9
(en)
*
|
1997-04-07 |
2006-07-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20020173629A1
(en)
*
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
DE19722888A1
(de)
*
|
1997-05-28 |
1998-12-03 |
Thomas Prof Dr Huenig |
Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
AU2469299A
(en)
*
|
1998-01-23 |
1999-08-09 |
Cornell Research Foundation Inc. |
Purified populations of stem cells
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ES2230848T3
(es)
*
|
1998-04-28 |
2005-05-01 |
Smithkline Beecham Corporation |
Anticuerpos monoclonales con inmunogenicidad reducida.
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
IL140701A0
(en)
|
1998-07-13 |
2002-02-10 |
Univ Texas |
Cancer treatment methods using antibodies to aminophospholipids
|
TR200100560T2
(tr)
*
|
1998-08-18 |
2002-05-21 |
The Regents Of The University Of California |
EGF-R Antagonistlerinin uygulanmasıyla nefes yolunda mukus üretiminin önlenmesi
|
EE200100603A
(et)
*
|
1999-05-14 |
2003-02-17 |
Imclone Systems Incorporated |
Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
US20010051147A1
(en)
*
|
2000-03-27 |
2001-12-13 |
Van De Winkel Jan G.J. |
Methods for immunostimulation using binding agents for the Fc receptor of immunoglobulin A
|
WO2002011677A2
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
PL206142B1
(pl)
*
|
2001-01-09 |
2010-07-30 |
Merck Patent Gmbhmerck Patent Gmbh |
Kompozycja i zestaw farmaceutyczny do leczenia nowotworów i przerzutów nowotworowych oraz ich zastosowanie
|
WO2002066058A1
(en)
*
|
2001-02-19 |
2002-08-29 |
Merck Patent Gmbh |
Modified anti-egfr antibodies with reduced immunogenicity
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
RU2316337C2
(ru)
|
2001-04-24 |
2008-02-10 |
Мерк Патент Гмбх |
КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
|
PL363322A1
(en)
*
|
2001-05-08 |
2004-11-15 |
Merck Patent Gmbh |
Combination therapy using anti-egfr antibodies and anti-hormonal agents
|
EP1392359B2
(en)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
JP2005508298A
(ja)
*
|
2001-06-20 |
2005-03-31 |
イムクローン システムズ インコーポレイティド |
アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
|
EP1399484B1
(en)
*
|
2001-06-28 |
2010-08-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP2005526482A
(ja)
*
|
2001-08-10 |
2005-09-08 |
イムクローン システムズ インコーポレイティド |
Vegfr−1を発現する幹細胞の単離および動員
|
JP2005531488A
(ja)
*
|
2001-10-09 |
2005-10-20 |
ザ・ユニバーシティ・オブ・シンシナティ |
甲状腺癌を処置するためのegf受容体阻害剤
|
AU2003213231A1
(en)
|
2002-02-25 |
2003-09-09 |
Elan Pharmaceuticals, Inc. |
Administration of agents for the treatment of inflammation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
AU2003213687A1
(en)
*
|
2002-03-04 |
2003-09-22 |
Imclone Systems Incorporated |
Human antibodies specific to kdr and uses thereof
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
BR122019027966B8
(pt)
|
2002-05-02 |
2021-07-27 |
Wyeth Corp |
conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
|
MXPA04011550A
(es)
*
|
2002-05-20 |
2005-02-17 |
Abgenix Inc |
Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
|
US7893218B2
(en)
|
2003-06-16 |
2011-02-22 |
Stowers Institute For Medical Research |
Antibodies that specifically bind SOST peptides
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
ATE328906T1
(de)
*
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
ES2358730T3
(es)
|
2002-07-15 |
2011-05-13 |
Board Of Regents, The University Of Texas System |
Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
WO2004032961A1
(en)
*
|
2002-10-10 |
2004-04-22 |
Merck Patent Gmbh |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
GB0228832D0
(en)
*
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
WO2004044161A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Fraunhofer Usa |
Expression of foreign sequences in plants using trans-activation system
|
US7683238B2
(en)
|
2002-11-12 |
2010-03-23 |
iBio, Inc. and Fraunhofer USA, Inc. |
Production of pharmaceutically active proteins in sprouted seedlings
|
US7692063B2
(en)
*
|
2002-11-12 |
2010-04-06 |
Ibio, Inc. |
Production of foreign nucleic acids and polypeptides in sprout systems
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
JP4741242B2
(ja)
|
2002-11-26 |
2011-08-03 |
アボット バイオセラピューティクス コーポレイション |
新脈管形成を調節するα5β1インテグリンへのキメラ及びヒト化抗体
|
US7276589B2
(en)
*
|
2002-11-26 |
2007-10-02 |
Pdl Biopharma, Inc. |
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
|
US7285268B2
(en)
*
|
2002-11-26 |
2007-10-23 |
Pdl Biopharma, Inc. |
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
|
EP1578801A2
(en)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
EP2192172B1
(en)
*
|
2003-02-03 |
2014-12-03 |
iBio, Inc. |
System for expression of genes in plants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
EP1625165A2
(en)
*
|
2003-04-03 |
2006-02-15 |
Protein Design Labs, Inc. |
Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
|
CN103074316B
(zh)
|
2003-05-22 |
2015-10-21 |
美国弗劳恩霍夫股份有限公司 |
用于表达、传递及纯化目标多肽的重组载体分子
|
CN101966338A
(zh)
|
2003-06-09 |
2011-02-09 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
BRPI0415457A
(pt)
*
|
2003-10-16 |
2006-12-05 |
Micromet Ag |
constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
|
DE10355904A1
(de)
*
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
CA2552658A1
(en)
*
|
2004-01-07 |
2005-07-28 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
WO2005081905A2
(en)
*
|
2004-02-20 |
2005-09-09 |
Fraunhofer Usa Inc. |
Systems and methods for clonal expression in plants
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
EP1735348B1
(en)
*
|
2004-03-19 |
2012-06-20 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
DK1755659T3
(da)
*
|
2004-03-24 |
2012-02-27 |
Abbott Biotherapeutics Corp |
Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
PL2343380T3
(pl)
|
2004-11-16 |
2020-03-31 |
Humanigen, Inc. |
Wymiana kasety dla regionu zmiennego immunoglobuliny
|
CN101102791B
(zh)
*
|
2004-11-18 |
2011-12-14 |
英克隆有限责任公司 |
抗血管内皮生长因子受体-1的抗体
|
RU2488597C2
(ru)
|
2005-02-07 |
2013-07-27 |
Гликарт Биотехнологи Аг |
Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
|
HUE038768T2
(hu)
*
|
2005-02-18 |
2018-11-28 |
Abraxis Bioscience Llc |
Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
CA2605781A1
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
US20080044420A1
(en)
*
|
2005-05-11 |
2008-02-21 |
Heavner George A |
Anti-IL-13 antibodies, compositions, methods and uses
|
KR101446025B1
(ko)
*
|
2005-08-03 |
2014-10-01 |
아이바이오, 인크. |
면역글로불린의 생산을 위한 조성물 및 방법
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
ATE520979T1
(de)
*
|
2005-08-24 |
2011-09-15 |
Bristol Myers Squibb Co |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP2009511524A
(ja)
|
2005-10-11 |
2009-03-19 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ケモカイン発現のegfr依存調節ならびに腫瘍とその副作用の治療及び診断に与えるケモカイン発現調節の影響
|
AU2006316629A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
US20090214541A1
(en)
|
2006-01-04 |
2009-08-27 |
L'instut National De La Sante Et De La Recherche Medicale |
Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
|
AU2007215080A1
(en)
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Influenza antigens, vaccine compositions, and related methods
|
JP2009526780A
(ja)
*
|
2006-02-13 |
2009-07-23 |
フラウンホーファー ユーエスエー, インコーポレイテッド |
Hpv抗原、ワクチン組成物、および関連する方法
|
US8277816B2
(en)
*
|
2006-02-13 |
2012-10-02 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
RU2429014C2
(ru)
*
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
SI2117520T1
(sl)
|
2006-12-14 |
2019-01-31 |
Abraxis Bioscience, Llc |
Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
|
JP2010513321A
(ja)
*
|
2006-12-22 |
2010-04-30 |
ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
|
EP3345607B1
(en)
|
2006-12-29 |
2022-10-26 |
Ossifi-Mab LLC |
Methods of altering bone growth by administration of sost or wise antagonist or agonist
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
DK2132229T3
(en)
*
|
2007-03-01 |
2016-06-20 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
|
US9023356B2
(en)
|
2007-03-15 |
2015-05-05 |
Ludwig Institute For Cancer Research Ltd |
Treatment method using EGFR antibodies and SRC inhibitors and related formulations
|
EP2152301A4
(en)
*
|
2007-04-28 |
2010-07-28 |
Fraunhofer Usa Inc |
TRYPANOSOME ANTIGENS, VACCINE COMPOSITIONS AND RELATED METHODS
|
JP2010528647A
(ja)
|
2007-06-06 |
2010-08-26 |
ドマンティス リミテッド |
ポリペプチド、抗体可変ドメインおよびアンタゴニスト
|
WO2009000099A2
(en)
|
2007-06-25 |
2008-12-31 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
EP2526967A1
(en)
|
2007-07-17 |
2012-11-28 |
Merck Patent GmbH |
Engineered anti-alpha v-integrin hybrid antibodies
|
KR20100040877A
(ko)
*
|
2007-07-27 |
2010-04-21 |
패시트 바이오테크 코포레이션 |
티로신 키나제 억제제, 및 인테그린 알파1베타5(cd49e)에 대한 항체를 포함하는 약학 조합물
|
ES2609915T3
(es)
|
2007-08-14 |
2017-04-25 |
Ludwig Institute For Cancer Research Ltd. |
Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
|
US20110059130A1
(en)
*
|
2007-08-20 |
2011-03-10 |
Fraunhofer Usa, Inc. |
Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
KR20100099128A
(ko)
*
|
2007-10-19 |
2010-09-10 |
파르마 마르 에스.에이. |
개선된 항암치료
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
US20110015135A1
(en)
*
|
2008-03-07 |
2011-01-20 |
Pharma Mar S.A. |
Antitumoral Treatments
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
KR101706255B1
(ko)
|
2008-08-29 |
2017-02-14 |
심포젠 에이/에스 |
재조합 항-표피 성장 인자 수용체 항체 조성물
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
SG171812A1
(en)
*
|
2008-12-04 |
2011-07-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
CN102325549A
(zh)
|
2009-03-31 |
2012-01-18 |
罗氏格黎卡特股份公司 |
用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
AU2010233995A1
(en)
|
2009-04-07 |
2011-09-08 |
Roche Glycart Ag |
Bispecific anti-ErbB-2/anti-c-Met antibodies
|
WO2010129609A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
Antibodies and methods of use thereof
|
WO2011015918A2
(en)
*
|
2009-08-03 |
2011-02-10 |
Avesthagen Limited |
Vectors and compounds for expression of recombinant cetuximab
|
BR112012004710A2
(pt)
|
2009-09-01 |
2016-08-16 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e uso das mesmas
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
MX2012004415A
(es)
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
WO2011097633A2
(en)
*
|
2010-02-08 |
2011-08-11 |
Board Of Regents, The University Of Texas System |
Egf receptor mimicking peptides
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
RU2016119999A
(ru)
|
2010-03-29 |
2018-11-08 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Способы лечения онкологических заболеваний
|
EP2552957A4
(en)
|
2010-03-29 |
2013-11-20 |
Zymeworks Inc |
ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
|
NZ602635A
(en)
|
2010-03-29 |
2014-12-24 |
Abraxis Bioscience Llc |
Methods of enhancing drug delivery and effectiveness of therapeutic agents
|
KR101539684B1
(ko)
|
2010-05-14 |
2015-07-27 |
애브비 인코포레이티드 |
Il-1 결합 단백질
|
US8071093B1
(en)
*
|
2010-05-17 |
2011-12-06 |
Samsung Electronics Co., Ltd. |
Fully human anti-epidermal growth factor receptor antibodies
|
US9399071B2
(en)
|
2010-06-04 |
2016-07-26 |
Abraxis Bioscience, Llc |
Methods of treatment of pancreatic cancer
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012024659A2
(en)
|
2010-08-20 |
2012-02-23 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN105399831A
(zh)
|
2010-10-29 |
2016-03-16 |
伊缪诺金公司 |
非拮抗性egfr结合分子及其免疫偶联物
|
MX2013004761A
(es)
|
2010-10-29 |
2013-08-27 |
Immunogen Inc |
Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
|
CA2821976A1
(en)
|
2010-12-21 |
2012-09-13 |
Abbvie Inc. |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
JP6320042B2
(ja)
|
2011-02-11 |
2018-05-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
前立腺癌治療のための抗アルファ−vインテグリン抗体
|
US20140127240A1
(en)
|
2011-04-21 |
2014-05-08 |
Bayer Pharma Aktiengesellschaft |
Novel Binder-Drug Conjugates (ADCs) and Use of Same
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
UY34054A
(es)
|
2011-05-02 |
2012-11-30 |
Millennium Pharm Inc |
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
WO2013009868A1
(en)
|
2011-07-11 |
2013-01-17 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
WO2013009767A2
(en)
|
2011-07-12 |
2013-01-17 |
Epitomics, Inc. |
Facs-based method for obtaining an antibody sequence
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
JP6076357B2
(ja)
|
2011-10-10 |
2017-02-08 |
シティ・オブ・ホープCity of Hope |
メディトープおよびメディトープ結合性抗体ならびにそれらの使用
|
EP2766497A1
(en)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
BR112014009925B1
(pt)
|
2011-10-28 |
2022-09-20 |
Teva Pharmaceuticals Australia Pty Ltd |
Construtores de polipeptídeos e seus usos
|
EP2794010A4
(en)
|
2011-11-21 |
2015-10-21 |
Immunogen Inc |
METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
|
AU2012362326A1
(en)
|
2011-12-30 |
2014-07-24 |
Abbvie Inc. |
Dual variable domain immunoglobulins against IL-13 and/or IL-17
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
EP2914626A2
(en)
|
2012-11-01 |
2015-09-09 |
Abbvie Inc. |
Stable dual variable domain immunoglobulin protein formulations
|
EP2916835A4
(en)
|
2012-11-12 |
2016-07-27 |
Redwood Bioscience Inc |
COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
CA2890906A1
(en)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Pictet-spengler ligation for protein chemical modification
|
LT3447069T
(lt)
|
2012-11-21 |
2020-12-10 |
Janssen Biotech, Inc. |
Bispecifiniai egfr/c-met antikūnai
|
AU2013362134B2
(en)
|
2012-12-21 |
2018-07-05 |
Sykehuset Sorlandet Hf |
EGFR targeted therapy of neurological disorders and pain
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN105209493B
(zh)
|
2013-03-14 |
2019-05-03 |
德克萨斯州大学系统董事会 |
用于诊断和治疗用途的her3特异性单克隆抗体
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014144600A2
(en)
|
2013-03-15 |
2014-09-18 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
DK2986312T3
(da)
|
2013-04-19 |
2022-02-14 |
Cytune Pharma |
Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
|
PL3677591T3
(pl)
|
2013-04-29 |
2023-06-26 |
Teva Pharmaceuticals Australia Pty Ltd |
Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3044236A2
(en)
|
2013-09-12 |
2016-07-20 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015070972A1
(en)
|
2013-11-12 |
2015-05-21 |
Atlab Pharma |
Human igg1 derived antibody with pro-apoptotic activity
|
US10273303B2
(en)
|
2013-11-13 |
2019-04-30 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
PT3086814T
(pt)
|
2013-12-23 |
2020-09-04 |
Bayer Pharma AG |
Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
KR102486180B1
(ko)
|
2014-06-06 |
2023-01-11 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
JP5924795B2
(ja)
|
2014-06-13 |
2016-05-25 |
テンボロン オイ |
複合体
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
RU2017113001A
(ru)
|
2014-09-17 |
2018-10-17 |
Мерк Патент Гмбх |
Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости
|
KR20170052690A
(ko)
|
2014-09-17 |
2017-05-12 |
메르크 파텐트 게엠베하 |
고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
|
AU2015327824B2
(en)
|
2014-10-02 |
2021-01-07 |
City Of Hope |
Multivalent meditopes, meditope-binding antibodies and uses thereof
|
WO2016065329A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
CA2965414C
(en)
|
2014-10-29 |
2024-01-09 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon .alpha.2.beta. variants
|
US9982057B2
(en)
|
2014-11-17 |
2018-05-29 |
Pelican Therapeutics, Inc. |
Human TNFRSF25 antibody
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
SG10201908685QA
(en)
|
2015-06-22 |
2019-10-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
WO2017079419A1
(en)
|
2015-11-05 |
2017-05-11 |
The Regents Of The University Of California |
Cells labelled with lipid conjugates and methods of use thereof
|
JP7034914B2
(ja)
|
2015-11-23 |
2022-03-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
線維症および/または線維性疾患の治療のための抗α-vインテグリン抗体
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
JP7155008B2
(ja)
|
2016-03-14 |
2022-10-18 |
ウニヴァーシテテット イ オスロ |
変化されたFcRnを有する改変された免疫グロブリン
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
BR112018075222A2
(pt)
|
2016-06-09 |
2019-03-19 |
Pelican Therapeutics, Inc |
anticorpos anti-tnfrsf25
|
IL263542B1
(en)
|
2016-06-14 |
2024-06-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
EP3919518A1
(en)
|
2016-06-15 |
2021-12-08 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
WO2018014067A1
(en)
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
WO2018114798A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
EP3558388A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
JP7030811B2
(ja)
|
2016-12-21 |
2022-03-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc)
|
JP7050333B2
(ja)
|
2017-03-24 |
2022-04-08 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
US20210186880A1
(en)
|
2018-08-03 |
2021-06-24 |
Brown University |
Oral formulations with increased uptake
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
CN113015747A
(zh)
|
2018-10-19 |
2021-06-22 |
默克专利股份公司 |
用于治疗结肠直肠癌的阿比妥单抗
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
EP4143234A1
(en)
|
2020-04-26 |
2023-03-08 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Modified immunoglobulins
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
KR20220001106A
(ko)
*
|
2020-06-29 |
2022-01-05 |
(주)메디톡스 |
고농도 항-vegf 항체 제제 및 이에 사용하기 위한 항-vegf 항체
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
JP2024521969A
(ja)
|
2021-06-14 |
2024-06-04 |
セントロ デ インミュノロヒア モレキュラル |
低酸素血症性急性呼吸不全患者の治療における上皮成長因子受容体に対するモノクローナル抗体の使用
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024126660A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Combination therapy for cancer treatment
|